Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) insider Preston Klassen sold 31,445 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $39,620.70. Following the sale, the insider now directly owns 36,055 shares in the company, valued at approximately $45,429.30. The trade was a 46.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Regulus Therapeutics Stock Performance

Shares of RGLS opened at $1.27 on Thursday. Regulus Therapeutics Inc. has a fifty-two week low of $1.08 and a fifty-two week high of $3.79. The firm’s 50-day simple moving average is $1.52 and its two-hundred day simple moving average is $1.59.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, equities analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Institutional Investors Weigh In On Regulus Therapeutics

A number of institutional investors have recently modified their holdings of RGLS. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics in the 3rd quarter worth about $10,154,000. Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics during the 3rd quarter valued at about $1,403,000. Bank of New York Mellon Corp purchased a new position in Regulus Therapeutics in the second quarter worth about $352,000. The Manufacturers Life Insurance Company bought a new position in shares of Regulus Therapeutics in the third quarter worth approximately $204,000. Finally, Tyche Wealth Partners LLC grew its holdings in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 95,694 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.